Back to mobile site

More on LABT

- Summary
- Chart
- Profile
- Historical

Data

- Earnings

Upcoming Events

- Earnings (9/2/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

(NQ:LABT)
Delayed: 3.06 -0.35 (10.26%)
Prev. Close $3.41  
Open$3.55 
52 Wk High$ 
52 Wk Low$ 
Day High$3.55 
Day Low$2.77 
P/E N/A  
EPS$ 
Volume2,010,304 

Friends, Peers and Foes (?): ASBP, ATYR, COCH, CTSO, IMNN (more...)

Jul 22, 2026 08:03 AM Lakewood-Amedex shares resistance data for antibiotic candidate Nu-3
Jul 22, 2026 08:02 AM Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria
Jul 15, 2026 04:16 PM Form 8-K Lakewood-Amedex Biothera For: Jul 15
Jul 15, 2026 08:02 AM Lakewood-Amedex reports preclinical safety data for Nu-3 gel trial
Jul 15, 2026 08:02 AM Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel
Jul 7, 2026 08:03 AM Lakewood-Amedex backs PASTEUR Act, plans Phase 2 trial for Nu-3
Jul 7, 2026 08:02 AM Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance
Jun 26, 2026 08:35 AM Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
Jun 25, 2026 08:02 AM Lakewood-Amedex names USC professor to chair diabetic foot ulcer trial
Jun 25, 2026 08:02 AM Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D., Ph.D., as Study Chair for Phase 2a Trial of Nu-3 in Infected Diabetic Foot Ulcers
View All Articles

Entities mentioned with LABT

View All Entities